Leap Therapeutics, Inc.
LPTX
$0.2896
-$0.0204-6.58%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 1.82M | 3.01M | 3.01M | 2.94M | 3.37M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 12.35M | 15.86M | 16.13M | 18.35M | 21.00M |
Operating Income | -12.35M | -15.86M | -16.13M | -18.35M | -21.00M |
Income Before Tax | -16.64M | -15.44M | -15.55M | -17.47M | -20.36M |
Income Tax Expenses | -- | -- | -123.00K | 708.00K | -- |
Earnings from Continuing Operations | -16.64M | -15.44M | -15.43M | -18.18M | -20.36M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -16.64M | -15.44M | -15.43M | -18.18M | -20.36M |
EBIT | -12.35M | -15.86M | -16.13M | -18.35M | -21.00M |
EBITDA | -12.35M | -15.86M | -16.13M | -18.35M | -21.00M |
EPS Basic | -0.40 | -0.37 | -0.38 | -0.44 | -0.52 |
Normalized Basic EPS | -0.18 | -0.23 | -0.47 | -0.26 | -0.32 |
EPS Diluted | -0.40 | -0.37 | -0.38 | -0.44 | -0.52 |
Normalized Diluted EPS | -0.18 | -0.23 | -0.47 | -0.26 | -0.32 |
Average Basic Shares Outstanding | 41.45M | 41.27M | 41.25M | 41.21M | 39.12M |
Average Diluted Shares Outstanding | 41.45M | 41.27M | 41.25M | 41.21M | 39.12M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |